Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Erasca
Biotech
Erasca erases part of pipeline after revealing mixed cancer data
Erasca put a KRAS inhibitor on the back burner in response to the “increasingly competitive landscape for small- and mid-cap biopharma companies.”
Nick Paul Taylor
Jun 6, 2023 10:00am
Erasca slides a Novartis melanoma med into pipeline for $20M
Dec 9, 2022 10:50am
Fierce Biotech's 2021 Fierce 15
Sep 27, 2021 3:00am
Erasca nabs $300M IPO to attack cancer's favorite pathway
Jul 16, 2021 10:10am